drugset / Trial / NCT05834062

Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

NCT05834062

Phase 2 Withdrawn University of Minnesota
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the use of phentermine and topiramate compared with placebo in helping adolescents who are at high risk for developing obesity to lose weight

Timeline

Start
2023-10-17
Primary completion
2026-08
Completion
2027-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentermine Small molecule 7.5 mg Oral
Subject Topiramate Small molecule 46 mg Oral

Indications

No indication recorded.